QCG
STRO icon

Quadrant Capital Group’s Sutro Biopharma STRO Stock Holding History

Quadrant Capital Group’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31
Closed -$1.08K – 2795
2024
Q3 		$1.08K Buy
+31
New +$1.22K ﹤0.01% 2584
2023
Q3 		– Sell
-198
Closed -$9.19K – 2765
2023
Q2 		$9.19K Hold
198
– – ﹤0.01% 2027
2023
Q1 		$9.13K Hold
198
– – ﹤0.01% 2062
2022
Q4 		$16K Hold
198
– – ﹤0.01% 1753
2022
Q3 		$11K Hold
198
– – ﹤0.01% 1867
2022
Q2 		$10K Buy
+198
New +$11.1K ﹤0.01% 1679

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Quadrant Capital Group's STRO Position: Q4 2024 in Review

Quadrant Capital Group sold out of Sutro Biopharma (STRO) in Q4 2024, closing a stake of 31 shares — an estimated $1.08K sold.

Quadrant Capital Group first reported a position in STRO in Q2 2022 and held it in 6 quarters. The position peaked at $16K in Q4 2022. 122 funds tracked by Wall St. Rank hold STRO as of Q4 2024.

  • Quadrant Capital Group reported no remaining Sutro Biopharma position as of Q4 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 31 Sutro Biopharma shares in Q4 2024, an estimated $1.08K.
  • Quadrant Capital Group first reported a position in Sutro Biopharma in Q2 2022 and held it in 6 quarters.
  • Quadrant Capital Group's Sutro Biopharma position peaked at $16K in Q4 2022.
  • 122 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2024.

Based on Quadrant Capital Group's 13F filing for Q4 2024, filed 13 Feb 2025.